Ko, Yi-An
Billheimer, Jeffrey T.
Lyssenko, Nicholas N.
Kueider-Paisley, Alexandra
Wolk, David A.
Arnold, Steven E.
Leung, Yuk Yee
Shaw, Leslie M.
Trojanowski, John Q.
Kaddurah-Daouk, Rima F.
Kling, Mitchel A.
Rader, Daniel J.
Funding for this research was provided by:
American Heart Association (14SDG20230024)
National Institutes of Health (5P30AG010124-27, 5P30AG010124-27)
National Institute on Aging (RF1 AG0151550, RF1 AG0151550)
Article History
Received: 25 March 2022
Accepted: 6 November 2022
First Online: 26 December 2022
Declarations
:
: All subjects gave written informed consent under research protocols approved by the University of Pennsylvania Institutional Review Board and agreed to the use of their data for research purposes. Samples were retrieved from the biobank of the Center for Neurodegenerative Disease Research (CNDR) at the Perelman School of Medicine, University of Pennsylvania, with approval from its governing body. Clinical, demographic, and genotype data were obtained from the Integrated Neurodegenerative Diseases Database maintained by CNDR using structured queries.
: Not applicable.
: R.F.K.-D. is inventor on key patents in the field of metabolomics including applications for Alzheimer’s disease. She holds equity in Metabolon Inc. R.F.K-D. formed Chymia LLC and PsyProtix, a Duke University biotechnology spinout aiming to transform the treatment of mental health disorders.L.M.S. received research support from NIH/NIA, Alzheimer’s Disease Neuroimaging Initiative (ADNI) (AG024904), and University of Pennsylvania ADCC Biomarker Core (AG010124), Michael J. Fox Foundation for Parkinson’s Research, Roche, and Lilly; provides QC oversight for Roche Elecsys CSF AD biomarker immunoassays for ADNI; and is a consultant for Roche, Lilly, and Novartis.D.A.W. reports grants from Merck, Biogen, and Eli Lilly/Avid and additional fees from GE Healthcare, Functional Neuromodulation, Eli Lilly, Qynapse, and Neuronix, all outside of this work.S.E.A. has received fees for serving on advisory boards for Allyx Therapeutics, Inc., Bob’s Last Marathon, Cassava, Cortexyme, Inc., Sage Therapeutics, Inc., vTv Therapeutics, Inc., and for consulting to AbbVie, Inc., Boyle Shaughnessy Law, Cognito Therapeutics, Inc., EIP Pharma, Inc., M3 Biotech, Inc., Orthogonal Neuroscience, Inc., and Risen Pharmaceutical Technology Co, Ltd. He has received sponsored research grant support from the following commercial entities: AbbVie, Inc., Amylyx, Inc., Athira Pharma, Inc., Chromadex, Inc., EIP Pharma, Inc., Janssen Pharmaceuticals, Inc., Novartis AG, Seer Biosciences, Inc., and vTv Therapeutics, Inc. He has received sponsored research grant support from the following non-commercial entities: Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Challenger Foundation, John Sperling Foundation, and the National Institutes of Health.D.J.R. serves on the scientific advisory boards of Alnylam, Novartis, Pfizer, and Verve Therapeutics and is a Founder of Vascular Strategies and Staten Biotechnologies. He has received sponsored research support from Biogen Inc.